Deutsche Bank AG restated their buy rating on shares of Impax Laboratories, Inc. (NASDAQ:IPXL) in a report issued on Tuesday morning. The firm currently has a $23.00 price objective on the specialty pharmaceutical company’s stock.

A number of other analysts have also recently commented on the company. Citigroup Inc. boosted their price target on Impax Laboratories to $23.00 and gave the stock a buy rating in a research report on Tuesday. Piper Jaffray Companies reissued a hold rating and issued a $17.00 price target on shares of Impax Laboratories in a research report on Sunday. Cantor Fitzgerald boosted their price target on Impax Laboratories from $20.00 to $25.00 and gave the stock an overweight rating in a research report on Monday, September 11th. Royal Bank Of Canada set a $17.00 price target on Impax Laboratories and gave the stock a hold rating in a research report on Thursday, August 10th. Finally, Canaccord Genuity set a $19.00 price target on Impax Laboratories and gave the stock a hold rating in a research report on Wednesday, August 9th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the stock. Impax Laboratories has an average rating of Hold and a consensus target price of $18.56.

Impax Laboratories (IPXL) opened at 20.95 on Tuesday. Impax Laboratories has a one year low of $7.75 and a one year high of $27.29. The company’s market cap is $1.50 billion. The firm has a 50-day moving average price of $19.12 and a 200 day moving average price of $15.63.

Impax Laboratories (NASDAQ:IPXL) last posted its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The firm had revenue of $202.08 million for the quarter, compared to the consensus estimate of $195.62 million. During the same quarter in the prior year, the business earned $0.21 EPS. The business’s revenue for the quarter was up 17.1% on a year-over-year basis. Equities analysts expect that Impax Laboratories will post $0.70 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first reported by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/impax-laboratories-inc-ipxl-receives-buy-rating-from-deutsche-bank-ag/1575384.html.

Hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio lifted its position in Impax Laboratories by 12.7% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 6,911 shares of the specialty pharmaceutical company’s stock valued at $111,000 after acquiring an additional 780 shares in the last quarter. Commerce Bank lifted its position in Impax Laboratories by 12.9% in the 1st quarter. Commerce Bank now owns 11,460 shares of the specialty pharmaceutical company’s stock valued at $145,000 after acquiring an additional 1,310 shares in the last quarter. Appleton Partners Inc. MA bought a new position in Impax Laboratories in the 2nd quarter valued at approximately $191,000. Advisory Services Network LLC bought a new position in Impax Laboratories in the 2nd quarter valued at approximately $207,000. Finally, Virtu KCG Holdings LLC bought a new position in Impax Laboratories in the 2nd quarter valued at approximately $231,000. 86.26% of the stock is currently owned by institutional investors and hedge funds.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.